Floatz logo

Atezolizumab

Urinary Bladder Cancer

Explore 23 assets in Urinary Bladder Cancer →
Floatz Rating
BB66/100
Confidence
Indicative
v0.2
Sponsor
National Cancer Institute (NCI)
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05564416CT.gov
Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial
—Withdrawn———
NCT05259319CT.gov
Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)
—Unknown———
NCT04902040CT.gov
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
—Terminated———
NCT03513952CT.gov
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
—Completed———
NCT03650348CT.gov
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
—Completed———
NCT03237780CT.gov
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer
—Active Not Recruiting———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Urinary Bladder Cancer

AssetSponsorPhaseRating
Atezolizumab (this asset)National Cancer Institute (NCI)P2BB · 66
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)Fred Hutchinson Cancer CenterP2BB
CarboplatinIambic Therapeutics, IncP2BB
TrastuzumabIambic Therapeutics, IncP2BB
PembrolizumabFred Hutchinson Cancer CenterP2BB
NivolumabM.D. Anderson Cancer CenterP2B
AdriamycinM.D. Anderson Cancer CenterP2B
Cis-Diamminedichloroplatinum IiG1 Therapeutics, Inc.P2B
CabozantinibNational Cancer Institute (NCI)P2B

+37 more in the Urinary Bladder Cancer cohort

Other indications for Atezolizumab

IndicationSponsorPhaseRating
Metastatic Neoplasm—P2/3BB · 71
Her2-Receptor Negative Breast Cancer—P2BB · 69
Bladder Transitional Cell Carcinoma—P3BB · 68

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Atezolizumab in Urinary Bladder Cancer. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/atezolizumab-urinary-bladder-cancer

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →